Skip Navigation


NDT Advance Access originally published online on July 30, 2008
Nephrology Dialysis Transplantation 2008 23(12):4002-4008; doi:10.1093/ndt/gfn416
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
23/12/4002    most recent
gfn416v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bommer, J.
Right arrow Articles by Bommer, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bommer, J.
Right arrow Articles by Bommer, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study

Juergen Bommer1, Gernot Asmus2, Martin Wenning3 and Gudrun Bommer4

1 Medical Clinic, University of Heidelberg, Heidelberg 2 KfH Dialysis Center Sonnenallee, St. Josef Krankenhaus, Berlin 3 Department of Nephrology, Augusta Krankenanstalten Bochum, Bochum 4 Dialysis Center Heidelberg, Heidelberg, Germany

Correspondence and offprint requests to: Juergen Bommer, Bergheimer Str. 59/61, 69115 Heidelberg, Germany. Tel: +49-6221-97900; Fax: +49-6221-184085; E-mail: juergen_bommer{at}t-online.de



  Abstract

Background. The different efficacy of subcutaneous and intravenous rHuEPO results in higher doses and costs in intravenously treated patients. Darbepoetin alfa has a different pharmacokinetic profile compared to rHuEPO, and previous clinical experience suggests that subcutaneous and intravenous darbepoetin alfa may have similar efficacy.

Objective. The aim of this study was to compare the efficacy of intravenous and subcutaneous darbepoetin alfa regarding haemoglobin levels and doses.

Methods. Patients treated with subcutaneous darbepoetin alfa for at least 6 months were randomized 1:1 to continue with subcutaneous treatment of darbepoetin alfa or to switch to the intravenous administration route. The application frequency was not altered. Darbepoetin alfa dose as well as haemoglobin concentrations were evaluated as per patient average at baseline (Week –3 ± 1), Week 24 ± 3 and Week 48 ± 3.

Results. One hundred fourteen patients in 9 German dialysis centres were included. Fifty-three patients were treated intravenously and 61 patients continued the subcutaneous therapy. Mean haemoglobin levels and mean weekly darbepoetin alfa dose did not change significantly in either treatment group.

Conclusions. Our data suggest that the darbepoetin alfa dose can be kept constant if patients are switched from subcutaneous to intravenous treatment.

Keywords: anaemia; darbepoetin alfa; haemodialysis; intravenous; subcutaneous

Received for publication: 29. 6.07
Accepted in revised form: 30. 6.08


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.